MetaCap

Perspective Therapeutics (CATX) vs Retension Pharmaceuticals (RTSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perspective Therapeutics is the larger company by market cap ($91.0 million vs $87.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-71.66%RTSN-0.19%
+61%-8%-78%
Oct 9, 20261 yearNov 20, 2026
CATX-71.66%RTSN-0.19%
+51%-13%-77%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus RTSN key metrics
MetricCATXRTSN
Share price$0.7538$10.51
Market cap$91.03M$87.57M
1-day change-3.85%-19.22%
YTD return-72.59%—
1-year return-63.93%—
5-year return-84.62%—
EPS (TTM)$-1.25$-2.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-103.12M—
52-week high$6.16$18.64
52-week low$0.73$9.23
Distance from 52-week high-87.76%-43.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1188.14%+391.63%
Average volume2.70M144.93K
Shares outstanding120.76M8.33M
Employees16312
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About Retension Pharmaceuticals

RTSN stock →

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CATX vs RTSN FAQ

Which is bigger, Perspective Therapeutics or Retension Pharmaceuticals?

Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $87.57M for Retension Pharmaceuticals (RTSN).

Are Perspective Therapeutics and Retension Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons